Because the suppression of tumor cell apoptosis further contributes to reduced treatment response, the inhibition of aberrant STAT3 activation emerges as a compelling HNSCC and CRC target (8, 14, 15). This evidence concerns the gene STAT3 and head and neck squamous cell carcinoma.